Polysensitisation is associated with more severe symptoms: The reality of patients with allergy
- PMID: 38676405
- DOI: 10.1111/cea.14486
Polysensitisation is associated with more severe symptoms: The reality of patients with allergy
Abstract
Background: Studying the sensitisation profiles of patients with allergies allows for a deeper understanding of the disease which may facilitate the selection of the best-personalised allergen immunotherapy. This observational, cross-sectional, multicentre study aimed to demonstrate the heterogeneity of the German population with allergies by analysing specific immunoglobulin E (sIgE) patterns towards aeroallergens and exploring the relationship between sensitisation and clinical symptoms.
Methods: In total, 500 patients with allergies from different regions of Germany were recruited based on their case histories, clinical allergic symptoms and skin prick test data for aeroallergens. Serum samples were analysed using ImmunoCAP assays to determine sIgE levels for 33 allergenic sources and 43 molecular allergens.
Results: Most patients (81%) were polysensitised. Betula verrucosa pollen was the most common cause of sensitisation (59%), followed by Phleum pratense (58%) and Dermatophagoides pteronyssinus (44%). The highest prevalence rates of molecular allergens were observed for Bet v 1 (84%) from birch pollen, Phl p 1 from grass pollen (82%), Der p 2 (69%) from mites and Fel d 1 (69%) from cat. Polysensitisation was significantly associated with the presence of asthma and the severity of rhinitis symptoms.
Conclusions: Our findings show a high rate of polysensitisation and emphasise the importance of molecular diagnosis for more precise and comprehensive insights into sensitisation patterns and their association with clinical symptoms. These data may help improve personalised diagnosis and immunotherapy adapted to the needs of individual patients in the region.
Keywords: aeroallergens; molecular diagnosis; personalised immunotherapy; polysensitisation.
© 2024 John Wiley & Sons Ltd.
References
REFERENCES
-
- Demoly P, Passalacqua G, Pfaar O, Sastre J, Wahn U. Management of the polyallergic patient with allergy immunotherapy: a practice‐based approach. Allergy Asthma Clin Immunol. 2016;12:2.
-
- Scala E, Abeni D, Asero R. Disease‐specific molecular profiles highlighted by radar graphic display. Int Arch Allergy Immunol. 2020;181(7):536‐539.
-
- Nelson HS. To mix or not to mix in allergy immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 2021;21(6):583‐589.
-
- Bahceciler NN, Yuruker O. Planning and approach to allergen‐specific immunotherapy in polyallergic patients. Immunotherapy. 2020;12(8):577‐585.
-
- Alba P, Moreno V, Arias‐Irigoyen J, et al. Safety evaluation of a multiallergen immunotherapy treatment in polyallergic patients. APOLO observational study. Immunotherapy. 2020;12(1):75‐87.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous